These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20421406)

  • 21. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
    AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
    Bekker A; Salvadori N; Rabie H; du Toit S; Than-In-At K; Groenewald M; Cressey R; Nielsen J; Capparelli EV; Lallemant M; Cotton MF; Cressey TR;
    Lancet HIV; 2024 Feb; 11(2):e86-e95. PubMed ID: 38296364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
    Gandhi M; Benet LZ; Bacchetti P; Kalinowski A; Anastos K; Wolfe AR; Young M; Cohen M; Minkoff H; Gange SJ; Greenblatt RM;
    J Acquir Immune Defic Syndr; 2009 Apr; 50(5):482-91. PubMed ID: 19408353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Penazzato M; Giaquinto C
    Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
    Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
    Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
    Umeh OC; Currier JS; Park JG; Cramer Y; Hermes AE; Fletcher CV
    J Clin Pharmacol; 2011 Dec; 51(12):1665-73. PubMed ID: 21233301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
    DiCenzo R; Peterson D; Cruttenden K; Morse G; Riggs G; Gelbard H; Schifitto G
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4328-31. PubMed ID: 15504860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
    Poirier JM; Robidou P; Jaillon P
    Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Goujard C; Vincent I; Meynard JL; Choudet N; Bollens D; Rousseau C; Demarles D; Gillotin C; Bidault R; Taburet AM
    Antimicrob Agents Chemother; 2003 Jan; 47(1):118-23. PubMed ID: 12499178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
    Moltó J; Valle M; Blanco A; Negredo E; DelaVarga M; Miranda C; Miranda J; Domingo P; Vilaró J; Tural C; Costa J; Barbanoj MJ; Clotet B
    Clin Pharmacokinet; 2007; 46(1):85-92. PubMed ID: 17201460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
    Hull MW; Harris M; Lima V; Guillemi S; Harrigan PR; Montaner JS
    J Clin Pharmacol; 2009 Feb; 49(2):155-61. PubMed ID: 19179294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
    Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
    N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
    Bartelink IH; Savic RM; Dorsey G; Ruel T; Gingrich D; Scherpbier HJ; Capparelli E; Jullien V; Young SL; Achan J; Plenty A; Charlebois E; Kamya M; Havlir D; Aweeka F
    Pediatr Infect Dis J; 2015 Mar; 34(3):e63-70. PubMed ID: 25742090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
    van Luin M; Van der Ende ME; Richter C; Visser M; Faraj D; Van der Ven A; Gelinck L; Kroon F; Wit FW; Van Schaik RH; Kuks PF; Burger DM
    AIDS; 2010 May; 24(8):1223-6. PubMed ID: 20299957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
    Jackson A; Hill A; Puls R; Else L; Amin J; Back D; Lin E; Khoo S; Emery S; Morley R; Gazzard B; Boffito M
    J Antimicrob Chemother; 2011 Mar; 66(3):635-40. PubMed ID: 21172791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.
    Ng J; Chiu YL; Awni W; Bernstein B; Causemaker SJ; Klein CE
    J Clin Pharmacol; 2012 Aug; 52(8):1248-54. PubMed ID: 21719718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.